Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZI-MA4-1 in MAGE-A4 Expressing Solid Malignancies
NCT07613723Phase 1Recruiting
- Sponsor
- Zelluna
- Start
- May 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ZI-MA4-1 in ovarian cancer, squamous cell carcinoma of the lung (SCCL), synovial sarcoma (SS) and 1 more, sponsored by Zelluna. Primary endpoint: Safety and tolerability of ZI-MA4-1 up to 5 years. Started May 2026; status: recruiting.
02
Drugs
ZI-MA4-1
03
Conditions
ovarian cancersquamous cell carcinoma of the lung (SCCL)synovial sarcoma (SS)head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT07613723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07613723.